Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Endometrial Mixed Cell Adenocarcinoma”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Testing effectiveness (Phase 2)Study completedNCT01935934
What this trial is testing

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Who this might be right for
Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Cell Adenocarcinoma+7 more
National Cancer Institute (NCI) 102
Early research (Phase 1)Study completedNCT00083213
What this trial is testing

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Cancer
Regeneron Pharmaceuticals 25
Testing effectiveness (Phase 2)Study completedNCT01210222
What this trial is testing

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell Adenocarcinoma+4 more
Gynecologic Oncology Group 35
Testing effectiveness (Phase 2)Study completedNCT00888173
What this trial is testing

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Adenocarcinoma+6 more
Gynecologic Oncology Group 45
Testing effectiveness (Phase 2)Looking for participantsNCT05112601
What this trial is testing

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+6 more
National Cancer Institute (NCI) 81
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Active Not RecruitingNCT03120624
What this trial is testing

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

Who this might be right for
Metastatic Endometrial CarcinomaRecurrent Endometrial AdenocarcinomaRecurrent Endometrial Carcinoma+7 more
Mayo Clinic 34
Testing effectiveness (Phase 2)Study completedNCT02728258
What this trial is testing

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
NRG Oncology 11
Early research (Phase 1)Study completedNCT00575952
What this trial is testing

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Who this might be right for
Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Adenocarcinoma+8 more
Gynecologic Oncology Group 27
Early research (Phase 1)Study completedNCT00066404
What this trial is testing

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions

Who this might be right for
Cancer
Abramson Cancer Center at Penn Medicine
Not applicableLooking for participantsNCT06349642
What this trial is testing

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Who this might be right for
Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical Carcinoma+24 more
Mayo Clinic 324
Not applicableStudy completedNCT00897442
What this trial is testing

Collecting Tumor Samples From Patients With Gynecological Tumors

Who this might be right for
Borderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical Adenocarcinoma+83 more
Gynecologic Oncology Group 275
Large-scale testing (Phase 3)Active Not RecruitingNCT03914612
What this trial is testing

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Who this might be right for
Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more
National Cancer Institute (NCI) 813
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Early research (Phase 1)Study completedNCT00659568
What this trial is testing

Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Who this might be right for
Breast CancerEndometrial CancerKidney Cancer+3 more
London Health Sciences Centre 28
Early research (Phase 1)Study completedNCT00004178
What this trial is testing

Gene Therapy in Treating Patients With Cancer

Who this might be right for
Cancer
Roger Williams Medical Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03660826
What this trial is testing

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Who this might be right for
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT01225887
What this trial is testing

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mucinous Adenocarcinoma+6 more
Gynecologic Oncology Group 37
Testing effectiveness (Phase 2)Study completedNCT01642082
What this trial is testing

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Adenocarcinoma+6 more
Gynecologic Oncology Group 28
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Load More Results
288